logo
Plus   Neg
Share
Email

Sanofi Launches Phase 3 Trials To Evaluate Isatuximab In Multiple Myeloma

Sanofi (SNYNF) announced the company has launched two new late-stage clinical studies to determine if isatuximab (an anti-CD38 antibody), when used in combination with other commonly used cancer treatments, might be an effective treatment option for certain people with multiple myeloma, a rare blood cancer.

IKEMA study is a 325-patient randomized, open-label, global multicenter Phase 3 trial that will compare isatuximab in combination with carfilzomib and dexamethasone against carfilzomib and dexamethasone in patients with relapsed and refractory multiple myeloma that have previously been treated with one-to-three lines of therapy.

IMROZ study is a 425-patient randomized, open-label, global multicenter Phase 3 trial that will compare isatuximab in combination with bortezomib, lenalidomide and dexamethasone against bortezomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma patients not eligible for transplant.

The company said both studies will evaluate progression-free survival as the primary endpoint. Key secondary endpoints include overall survival, overall response rate, depth of response, safety and quality of life.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Amazon.com Inc. said it plans to open a new corporate office in Manchester in 2019 and create more than 1,000 highly-skilled jobs in the UK. As part of the ramp up of its UK investment, Amazon will increase the capacity of its Scotland Development Centre and Cambridge Development Centre. The company's 1,000 new staffers will work on research and development in the UK. Ford will launch its new "Built Ford Proud" U.S. advertising campaign this weekend as the automaker grapples with slowing sales and plans to restructure its operations in order to cut costs. The ad campaign will highlight Ford's 115-year history of manufacturing cars and comes as the automaker intends to replace 75 percent of its U.S. lineup by 2020. The Procter & Gamble Company (PG) reported first-quarter core earnings per share of $1.12, an increase of three percent versus the prior year, as benefits from a lower tax rate due to implementation of the U.S. Tax Act was partially offset by a reduction in operating margin, driven largely by negative...
Follow RTT